DJS Antibodies Ltd designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. Dr David Llewellyn received his PhD in Clinical Medicine at the University of Oxford in 2014. Company created . Joe is the CSO and Co-Founder of DJS Antibodies. Copyright © 2020 DJS Antibodies. DJS utilises its proprietary HEPTAD technology, and its ability to discover leads against previously intractable GPCR targets, to discover and develop novel first-in-class therapeutic antibodies against key drivers of inflammatory disease. He loves discovery, and so is motivated by the pursuit of developing totally novel therapeutics. DJS Antibodies is discovering game-changing medicines to address recognised unmet medical need. Life Sciences . David Llewellyn December 22, 2020. DJS wins 2020 Innovation Award. Uciane joined OSI as a Principal in December 2019. He shares his secrets to success and provide us with insight into life in a startup. Enabled by HEPTAD, DJS is developing two lead programmes, a first-in-class antibody against a clinically validated but un-drugged target in diabetic nephropathy, and a programme that exploits novel biological insights to target myeloid cell-driven inflammation. This funding round will support the development of two candidate antibody therapeutics including an antibody therapeutic for chronic kidney disease (CKD), a long-term condition that leads to the irreversible and progressive loss of kidney function. View the profiles of professionals named "David Llewellyn" on LinkedIn. David Llewellyn. David Llewellyn . Dr. Kiener has led or contributed to the development of over 30 different clinical-stage therapeutics and seven approved drugs. BioMe Oxford, who develops a small ingestible gut-sampling device that can sample any part of the intestines in a non-invasive manner, was a mature team when they embarked on BioStars. David Llewellyn December 22, 2020. Previously, Dr. Kiener was President and Co-founder of Zyngenia Inc, a monoclonal antibody company developing drugs for oncology and inflammatory diseases. David Llewellyn Director of Marketing at supersmile New York, NY. Position. View David Llewellyn’s profile on LinkedIn, the world’s largest professional community. He cut his drug discovery teeth in the laboratory of Nobel Laureate Professor Sir James Black at the Wellcome Research Laboratories, subsequently working under the direction of Sir Salvador Moncada on serotonin receptor biology, which led to two IND candidate molecules, one of which - Zolmitriptan (Zomig®) – was launched in 1997 for migraine acute treatment. Early work, funded by Johnson&Johnson, has shown an unprecedented DJS Antibodies is an Oxford based biotechnology company founded with support from Johnson & Johnson Innovation and Oxford Sciences Innovation. We David Llewellyn, Co-founder and CEO of DJS Antibodies said: “We’re very excited to start working with LifeArc and such a strong group of investors. Contact: David Llewellyn (CEO) david.llewellyn@djsantibodies.com. We are looking to recruit a motivated person with a broad interest in disease biology and drug development. David Llewellyn. 1015243 and a charity registered in Scotland with the Office of the Scottish Charity Regulator no. SC037861. 2009 Sep;22(3):188-95. Having originally come from the sunny shores of Australia, David came to the UK to complete a PhD at the University of Oxford’s Jenner Institute supported by a Rhodes Scholarship. When he is not helping to navigate the choppy waters of R&D strategy and fund raising, Graeme is most likely to be found on the water casting flies at rising trout, walking the countryside in pursuit of Finnegan the English Setter or learning new woodworking skills in his quest to make order out of chaos. We share a vision of bringing first-in-class, high- impact therapeutic antibodies to the clinic, and this support will accelerate our growth towards becoming leaders in GPCR antibody discovery and development.” Privacy Policy. Dr. Kiener received a B.A. Cath loves travel, particularly safari trips to southern Africa, sea fishing (including tag and release), whale/dolphin watching (a member of the Whale and Dolphin Conservation Society); wildlife photography; Rugby Union – but just as a spectator! Founded: 2014 CEO: David Llewellyn Founder: David Llewellyn David Llewellyn CEO at DJS Antibodies Greater Oxford Area. We share a vision of bringing first-in-class, high-impact therapeutic antibodies to the clinic, and this support will accelerate our growth towards becoming leaders in GPCR antibody discovery and development.” BioMe Oxford. David Llewellyn, DJS Antibodies. Serum 25-hydroxyvitamin D concentration and cognitive impairment. Founded in 2015, we’ve raised over $600M of evergreen capital, building on Oxford’s renowned research legacy, to create a leading science and technology ecosystem and home for entrepreneurs. Our goal is to identify and invest in disruptive technologies which can truly transform the lives of patients. Prior to joining Atlas, Uciane was the Director of BD and Strategy at Compass Therapeutics, a US-based clinical stage I-O/immunology company which launched in 2015 with a $132M Series A led by F-Prime and Orbimed. in Biochemistry from Sir William Dunn School of Pathology at Oxford University, where he also pursued a postdoctoral fellowship. Pauline Lukey is a drug discovery and development professional with 20 years of experience at GlaxoSmithKline R&D. While not at work she is likely to be doing some sort of exercise (probably running) or be napping alongside one of her dogs. We are motivated by patient need and scientific opportunity. We have our own drug discovery and diagnostics development facilities, supported by experts in technology transfer and intellectual property who also provide services to other organisations. in Chemistry from Lancaster University and a D.Phil. DJS’ vision is to create safe, efficacious therapeutics that improve the lives of people with chronic inflammatory conditions. There are 200+ professionals named "David Llewellyn", who use LinkedIn to exchange information, ideas, and opportunities. Discovering new medicines is extremely difficult and most traditional methods fail. Prior to Compass, she spent 5 years working with large-small cap biopharma companies in Boston as a commercial strategy consultant. Joe loves working in a small and focussed team to solve problems creatively. brettwhatmough September 17, 2019. She also operated within the cell and gene therapy companies Korro Bio and AVROBIO [Nasdaq: AVRO], where she supported/co-led operations and financing, scientific, and commercial strategies. Leave a Reply Cancel Reply. Graeme then moved to the USA joining Roche Bioscience as the Head of Molecular Pharmacology and VP of CNS R&D, participating in the advancement of two further molecules through IND. She was involved in the launch of two companies, Quench Bio and Dyne Therapeutics, and served on several boards including Navitor, Quench, and Dyne. Company status Active Company type Private limited Company Incorporated on 21 July 2014. Cath has spent over 23 years acquiring significant depth of experience in antibody drug discovery and platform applications, alliance management and scientific leadership, working for cutting edge biotech and pharma companies, such as Cambridge Antibody Technology and Heptares Therapeutics. Since 2004, Amgen Ventures has invested in biotechnology companies to advance promising medicines and technologies that could ultimately make a difference for patients suffering from serious illnesses. We are looking to recruit a motivated person with a broad interest in disease biology and drug development. Developer of novel therapeutic monoclonal antibodies designed to target G-protein-coupled receptors (GPCRs). In a research career spanning 30 years, Michael has worked across academic, biotech and pharmaceutical industries, specialising in protein and antibody engineering. Lara likes a challenge, and so is keen to apply her skills to the field of drug discovery. David ... 294 others named David Llewellyn are on LinkedIn See others named David Llewellyn David is the CEO and Co-Founder of DJS Antibodies. Sehen Sie sich das Profil von David Llewellyn im größten Business-Netzwerk der Welt an. Sedgwick Yard is a Greater China-based venture firm dedicated to cross-border life science investments. In this episode of Cheeky Scientist Radio, we interview Dr. David Llewellyn, who is the CEO of DJS Antibodies, a successful R&D startup company. Pauline has a PhD in Immunology from the University of Pretoria and an MSc in microbial genetics from the University of the Witwatersrand. DJS Antibodies is an exemplar of the type of company we are trying to support—high-quality science, great scientists, strong start-up management all addressing a significant unmet patient need.”, Surinder MaanCommunications Manager, LifeArcsurinder.maan@lifearc.org. Cherwell Innovation Centre, Working at DJS Antibodies has allowed her to fulfil her aspirations as a scientist whilst also enjoying the team spirit, and dynamic, fast-paced environment that working in a small company offers. LifeArc is co-leading the c.£6 million funding with Sedgwick Yard, with new investment from Amgen Ventures and follow-on investment from Oxford Sciences Innovation (OSI). We share a vision of bringing first-in-class, high-impact therapeutic antibodies to the clinic, and this support will accelerate our growth towards becoming leaders in GPCR antibody discovery and development.”, David Holbrook, Head of Seed Fund, LifeArc said: “The LifeArc Seed Fund is delighted to be supporting DJS Antibodies on its work on GPCR antibody targets and helping translate the science on the next step towards the patient. David Llewellyn, DJS Antibodies. David has 2 jobs listed on their profile. https://lnkd.in/d96kSzy #innovation #biotech #amazingteam #cbas2020 There are 200 ... David Llewellyn CEO at DJS Antibodies Greater Oxford Area. PubMed. At DJS, we are developing a technology for isolating functional monoclonal antibodies against multi-pass integral membrane proteins such as GPCRs and ion channels. David Llewellyn Director of Marketing at supersmile New York, NY. Im Profil von David Llewellyn sind 10 Jobs angegeben. David Llewellyn. Chief among these is his involvement with DJS where, since 2015, he has shared with the founding team the inevitable thrills and spills of innovating new medicines. After graduating from Newcastle University with a BSc (Hons) in Pharmacology and a MRes in Neuroscience, Megan joined DJS Antibodies as a Research Assistant. In addition to working with DJS, Uciane currently represents OSI on the boards of PepGen, Scenic, MiroBio, and Dark Blue Therapeutics. Startup R&D Positions (Cheeky Scientist Radio). The successful applicant will … There are currently 6 active directors according to the latest confirmation statement submitted on 21st July 2020. The funding will also support the development of the HEPTAD platform into an industrialised monoclonal antibody (mAb) discovery process capable of identifying and screening novel therapeutic mAb candidates. In partnership with the University of Oxford, OSI creates fundamental technology companies, built on science. Name * Email * Website. 77 Heyford Park, In a past life, David was a competitive kayaker, most often found half way down a waterfall, though now is more likely to be found watching water fall onto his struggling vegetable garden. Joe holds a BSc in Biochemistry from Imperial College London and a PhD in antibody discovery and characterisation from the University of Oxford. In 2015, alongside a fellow DPhil graduate, Dr David Llewellyn, I founded DJS Antibodies where I am now chief scientific officer. The company was founded in 2014 and is headquartered in Bicester, United Kingdom. She led expert teams from candidate selection through to clinical proof of concept, designing and delivering over 20 individual clinical trials . Our model is built on collaboration, and we partner with a broad range of groups including medical research charities, research organisations, industry and academic scientists. Features. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. In 2014, he co-founded DJS antibodies with Dr Joe Illingworth and works full-time in the company as CEO. We match scientists with experienced entrepreneurs and patient capital to turn idea to impact, discovery to company. Features. November 2016 . The successful applicant will … Dr David Llewellyn CEO - DJS Antibodies David completed a DPhil at the University of Oxford where he worked on the development of vaccines against malaria. During his career Michael has authored more than 30 scientific papers and is a named inventor on a number of patents. CEO. OX25 5HD. Epidemiological observations have linked increased host iron with malaria susceptibility, and perturbed iron handling has been hypothesized to contribute to the potentially life-threatening anemia that may accompany blood-stage malaria infection. More for DJS ANTIBODIES LTD (09140967) Registered office address David Llewellyn, Cherwell Innovation Centre 77 Heyford Park, Upper Heyford, Bicester, Oxfordshire, OX25 5HD . DJS Antibodies Ltd is an active company incorporated on 21 July 2014 with the registered office located in Bicester, Oxfordshire. Separate to the Seed Fund, LifeArc has a Philanthropic Fund which provides grants to support medical research projects focused on the translation of rare diseases research. Ongoing collaboration extended for another 12 months and successfully progresses into late stage hit-to-lead optimisation phase Cambridge…, A new COVID-19 drug screening and resistance hub will be established in Scotland, based at the MRC-University…, LifeArc to fund two post-doctoral fellowships focused on drug discovery In November 2020, LifeArc initiated a new…, LifeArc is a charity registered with the Charity Commission for England and Wales no. After studying Joe worked as an academic on antibody induction and vaccination. Building a pipeline of unique assets enabled by a world-leading platform for antibody discovery. He retired as President & CEO of TVI in 2017 and now maintains a portfolio of advisory and non-executive Board roles in early stage biotech in USA, Europe and Japan. At DJS Antibodies equality, diversity and inclusion are really important to us. In this position, he also played a decision-making role in examining candidate therapeutics and platform technologies for in-licencing by GSK. LifeArc is a self-funded medical research charity. David Llewellyn. www.djsantibodies.com . Prior to Sucampo, he served as Chief Scientific Officer of Ambrx Inc., a company focused on developing antibody-drug conjugates. When it joined the programme, the team was looking for seed funding for the proof-of-concept and to widen their network. David remains committed to promoting values of equality and diversity throughout DJS and more broadly. DJS Antibodies . We developed HEPTAD, a revolutionary platform for antibody discovery, and now use this to create novel therapeutics that will have a meaningful impact on the lives of patients. When she is not working, Megan enjoys walking in the countryside with her springer spaniel, cycling, skiing, painting and baking. Prior to this, he served in a senior role at Domantis Ltd. Most recently, Dr. Kiener served as Chief Scientific Officer at Sucampo until the company's acquisition by Mallinckrodt in February 2018. In 2003, he joined Takeda Pharmaceutical Company where he built Takeda Ventures, Inc. (TVI), one of the first truly strategic Pharma corporate venture capital units. Epidemiological observations have long indicated that immunity against SM is acquired relatively rapidly, but prospective studies to investigate its immunological basis are logistically challenging and have rarely been undertaken. See the complete profile on LinkedIn and discover David’s connections and jobs at similar companies. BioMe Oxford, who develops a small ingestible gut-sampling device that can sample any part of the intestines in a non-invasive manner, was a mature team when they embarked on BioStars. Dr. Kiener has extensive experience in the Biotech and Biopharma industry and currently sits on the BODs or advisory committees of several Biotech companies. View David Llewellyn’s profile on LinkedIn, the world’s largest professional community. See the complete profile on LinkedIn and discover David’s connections and jobs at similar companies. Before joining DJS Lara completed an MRes in Biomedical Research at Imperial College. David has 4 jobs listed on their profile. She thrives in fast-paced environments and working in a close-knit team. Post investment, we support our partner companies in strategically approaching the Asian market, allowing their products to achieve a global footprint. She currently contributes towards the day-to-day running of the lab, development of new assays and management of our high-throughput antibody screening programmes. If you're looking to be surrounded by fantastic people and join an exciting team working on the cutting edge of drug discovery, get in touch! DJS Antibodies General Information Description. David is the CEO and Co-Founder of DJS Antibodies. David Llewellyn, co-founder and CEO of DJS Antibodies said: “We’re very excited to start working with LifeArc and such a strong group of investors. | © LifeArc 2021, Annual Report and Accounts April-December 2019, Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaboration, LifeArc funds COVID-19 drug screening hub at the University of Glasgow, LifeArc and Cleveland Clinic collaborate to advance early stage research towards patients. The LifeArc Seed Fund was launched in 2018 and to date it has committed £11m to 9 companies focussed on developing new therapeutics and biological modalities. His work covers mAb discovery and screening through to preclinical development of lead drugs, and he works closely with industry-leading experts as well as managing several government funded projects. David has more than 10 years’ experience in evolutionary immunology, antibody characterisation and myeloid cell biology, and he leads the team in our pursuit to create world changing antibody therapeutics. Uciane holds a PhD in cancer immunology from Dartmouth College. DJS Antibodies Ltd has been running for 6 years. While studying he co-founded and led the Good Lad Initiative, an organisation promoting positive masculinity and gender equality amongst groups of young men. In 2015 DJS Antibodies founded upon a vision of creating the next generation of antibody therapeutics. Huge congratulations to the DJS Antibodies team who won the Innovation Award at the 2020 Cherwell Business Awards on Friday. Oxford Sciences Innovation is a leading science and technology business. All rights reserved. He was formerly Head of Lead Discovery and Antibody Technologies within GSKs Biopharm R&D unit, where he led multidisciplinary project teams from start of discovery through to clinical candidate selection and beyond, working with a range of antibody formats and modalities including bispecifics. DJS ANTIBODIES – MEDICAL SCIENCES INTERN. Graeme is a Pharmaceutical industry veteran with 25+ years of direct engagement in therapeutic R&D, and a further 15 years’ experience in Pharma corporate venture. DJS ANTIBODIES LTD (09140967) Company status Active Correspondence address David Llewellyn, Cherwell Innovation Centre, 77 Heyford Park, Upper Heyford, Bicester, Oxfordshire, OX25 5HD. Accounts. ... David currently acts as the CEO of the Oxford based biotech company DJS Antibodies, which designs and discovers novel therapeutic monoclonal antibodies against … We invest in Life Sciences, Deep Tech, Healthtech, AI and Software to create companies taking on challenges like diagnosis and treatment of disease and cancer, hyper resolution microscopy, renewable energy, drones, nuclear fusion and quantum computing. We share a vision of bringing first-in-class, high-impact therapeutic antibodies to the clinic, and this support will accelerate our growth towards becoming leaders in GPCR antibody discovery and development.” Our mission is to advance translation of early science into health care treatments or diagnostics that can be taken through to full development and made available to patients. We believe our approach will enhance value to all stakeholders and benefit patients around the world. Contact: David Llewellyn (CEO) david.llewellyn@djsantibodies.com. David Llewellyn CEO at DJS Antibodies Greater Oxford Area. He's an avid cricket and football fan and spends his spare time getting out on the water. He was a leader in the establishment of HEPTAD, the mAb discovery engine at the heart of DJS, and now oversees all R&D activities within the company. She also lectures at the London School of Hygiene and Tropical Medicine, sits on the strategic advisory board of the EPSRC Prosperity Partnership and has published over 60 articles in peer reviewed journals. Throughout her studies, she developed an interest in disease biology and practical laboratory science. Vitamin D deficiency is associated with low mood and worse cognitive performance in … DJS Antibodies. Auf LinkedIn können Sie sich das vollständige Profil ansehen und mehr über die Kontakte von David Llewellyn und Jobs bei ähnlichen Unternehmen erfahren. Our success allows us to explore new approaches to stimulate and fund translation. Company Overview for DJS ANTIBODIES LTD (09140967) Filing history for DJS ANTIBODIES LTD (09140967) People for DJS ANTIBODIES LTD (09140967) More for DJS ANTIBODIES LTD (09140967) ... David Llewellyn, Cherwell Innovation Centre, 77 Heyford … , alongside a fellow DPhil graduate, Dr David Llewellyn Director of Marketing at supersmile new York, NY years... Is the CEO and Co-Founder of DJS Antibodies with Dr joe Illingworth and works full-time in biotech... The laboratory and onto the global stage she spent 5 years working with large-small biopharma... Discovers novel therapeutic monoclonal Antibodies designed to target G-protein-coupled receptors ( GPCRs ) on LinkedIn and discover ’. Assets enabled by a world-leading platform for antibody discovery studies, she 5... Chief scientific Officer discovering new medicines is extremely difficult and most traditional methods fail was... Dedicated to cross-border life science investments to widen their network on human therapeutics a China-based. An Oxford based biotechnology company founded with support from Johnson & Johnson Innovation and Oxford Innovation... Approved drugs success allows us to explore new approaches to stimulate and fund.. And so is keen to Apply her skills to the latest confirmation statement submitted on 21st July...., Neophore, Storm, Agomab, Synact ) of Pretoria and an in... Pauline Lukey is a named inventor on a number of patents alongside fellow... Llewellyn ( CEO ) david.llewellyn @ djsantibodies.com to impact david llewellyn djs antibodies discovery to company discovery, and at Squibb. Platform technologies for in-licencing by GSK scientific papers and is headquartered in Bicester, Kingdom! Zyngenia Inc, a monoclonal antibody company developing drugs for oncology and inflammatory diseases position he. David ’ s connections and jobs at similar companies 20 years of experience at GlaxoSmithKline R & D positions Cheeky... And practical laboratory science time I comment creates fundamental technology companies, built on science PhD clinical! How to Apply Please send a CV and cover letter by email david.llewellyn. Vision is to create safe, efficacious therapeutics that improve the lives patients. With large-small cap biopharma companies in strategically approaching the Asian market, allowing their products to a. Supersmile new York, NY currently 6 Active directors according to the field of drug discovery development. She is not working, Megan enjoys walking in the company 's acquisition by Mallinckrodt in February 2018 received PhD! Different clinical-stage therapeutics and seven approved drugs an interest in disease biology and drug development to,... Various European biotech companies explore new approaches to stimulate and fund translation Office the... Development of new assays and management of our high-throughput antibody screening programmes extremely difficult and most traditional fail. Is keen to Apply her skills to the development of new assays and management our... S connections and jobs at similar companies role in examining candidate therapeutics and platform technologies for in-licencing by GSK has! Bsc in Biochemistry from Imperial College London and a PhD in clinical Medicine at the University of Oxford OSI! Director in various European biotech companies and has worked with the DJS team since 2018 OX25! Works full-time in the biotech and biopharma industry and currently sits on the.! A technology for isolating functional monoclonal Antibodies designed to target G-protein-coupled receptors Sir William Dunn School Pathology. Interest in disease biology and drug development s profile on LinkedIn and discover David ’ s largest professional community therapeutics. She spent 5 years working with large-small cap biopharma companies in strategically approaching the Asian,... # biotech # amazingteam # cbas2020 Llewellyn DJ, Langa KM, IA... Thrives in fast-paced environments and working in a small and focussed team to solve problems creatively programme, the was... Amongst groups of young men also includes positions at MedImmune LLC, where he was Head of global &. Diversity throughout DJS and more broadly we ensure Oxford ’ s profile on LinkedIn and discover David ’ s science! And website in this position, he served in a close-knit team and the..., dr. Kiener has led or contributed to the development of over 30 different clinical-stage therapeutics and platform technologies in-licencing... Invest in disruptive technologies which can truly transform the lives of patients ( GPCRs ) and technology business benefit around! For oncology and inflammatory diseases to Compass, she developed an interest in disease biology drug... A named inventor on a number of patents malaria ( SM ) is a named on! Studying joe worked as an academic on antibody induction and vaccination, Dr David Llewellyn ( CEO ) david.llewellyn djsantibodies.com... 30 scientific papers and is a named inventor on a number of patents Director of at... Linkedin können Sie sich das vollständige Profil ansehen und mehr über die Kontakte David. Ceo at DJS Antibodies Ltd designs and discovers novel david llewellyn djs antibodies monoclonal Antibodies against G-protein-coupled receptors ( GPCRs ), company. I founded DJS Antibodies and so is motivated by the pursuit of totally... Non-Executive Director in various European biotech companies ( Synklino, Neophore, Storm,,... Proof of concept, designing and delivering over 20 individual clinical trials company 's acquisition by in... Has authored more than 30 scientific papers and is headquartered in Bicester, Kingdom. Game-Changing medicines to address recognised unmet medical need explore new approaches to stimulate and translation. At Domantis Ltd is to identify and invest in disruptive technologies which can truly transform the lives of.... Enjoys walking in the company as CEO David ’ s connections and jobs at similar companies clinical-stage therapeutics and approved. Marketing at supersmile new York, NY examining candidate therapeutics and seven approved drugs...! ) is a life-threatening complication of infection with Plasmodium falciparum to recruit a motivated person a. Das vollständige Profil ansehen und mehr über die Kontakte von David Llewellyn sind 10 jobs.. Discovering game-changing medicines to address recognised unmet medical need efficacious therapeutics that improve the lives of people with chronic conditions! Innovation is a named inventor on a number of patents sich das Profil. And worse cognitive performance in … David Llewellyn ’ s connections and jobs at companies! At similar companies Unternehmen erfahren browser for the proof-of-concept and to widen their network loves discovery and! Malaria ( SM ) is a named inventor on a number of patents he co-founded Antibodies! Of Pretoria and an MSc in microbial genetics from the University of the Scottish charity Regulator no can transform. Improve the lives of people with chronic inflammatory conditions strategically approaching the Asian market, their. Truly transform the lives of patients value to all stakeholders and benefit patients around the world headquartered Bicester! Full-Time in the countryside with her springer spaniel, cycling, skiing, painting baking... Also pursued a postdoctoral fellowship CH, Sheline YI, Roe CM, Birge SJ Morris! To turn idea to impact, discovery to company the global stage Sucampo, co-founded... Been running for 6 years company developing drugs for oncology and inflammatory diseases match with... Other resources to develop pioneering discoveries focused on human therapeutics science investments 's avid! Send a CV and cover letter by email to david.llewellyn @ djsantibodies.com on 21st 2020..., Synact ) biopharma industry and currently sits on the BODs or advisory committees of several biotech and... Developing a technology for isolating functional monoclonal Antibodies against multi-pass integral membrane proteins such as GPCRs and ion channels co-founded! Skiing, painting and baking and management of our high-throughput antibody screening programmes Biomedical Research at Imperial College has with! Painting and baking charity registered in Scotland with the DJS team since 2018,,. Professional with 20 david llewellyn djs antibodies of experience at GlaxoSmithKline R & D positions ( Cheeky Scientist Radio ) characterisation! All stakeholders and benefit patients around the world ’ s world-leading science moves out of the lab development... York, NY in-licencing by GSK, skiing, painting and baking Active type. And a PhD in cancer immunology from Dartmouth College decision-making role in examining candidate therapeutics and seven approved drugs Dartmouth. Development of over 30 different clinical-stage therapeutics and platform technologies for in-licencing by GSK with the University Oxford... At GlaxoSmithKline R & D Johnson & Johnson Innovation and Oxford Sciences Innovation and fibrosis latest confirmation statement on! Really important to us he also played a decision-making role in examining candidate therapeutics and platform technologies for by! Scientist Radio ) and provide us with insight into life in a startup Centre, 77 Park... Laboratory science has extensive experience in various therapy areas: including inflammation, autoimmunity fibrosis! Llewellyn im größten Business-Netzwerk der Welt an Centre, 77 Heyford Park, Upper Heyford, 5HD. An academic on antibody induction and vaccination in antibody discovery s largest professional community Neophore, Storm, Agomab Synact. Us to explore new approaches to stimulate and fund translation with low mood and cognitive... Of our high-throughput antibody screening programmes different clinical-stage therapeutics and seven approved drugs Llewellyn! 21St July 2020 the day-to-day running of the laboratory and onto the global stage safe, therapeutics! Novel therapeutics the team was looking for seed funding for the proof-of-concept and to widen their network, spent! 30 scientific papers and is headquartered in Bicester, United Kingdom 20 individual clinical trials he. I am now Chief scientific Officer the proof-of-concept and to widen their network when she is not,! Technologies which can truly transform the lives of people with chronic inflammatory conditions email and. Skiing, painting and baking headquartered in Bicester, United Kingdom spare time he loves discovery, and at Squibb! His career Michael has authored more than 30 scientific papers and is headquartered in Bicester United. 10 jobs angegeben ) is a drug discovery cover letter by email to @! Cm, Birge SJ, Morris JC equality, diversity and inclusion are really important to us has a in. ( Synklino, Neophore, Storm, Agomab, Synact ) amongst groups young. At Imperial College London and a PhD in antibody discovery than 30 scientific papers and is in. Llewellyn '' on LinkedIn, the team was looking for seed funding for proof-of-concept! Boston as a commercial strategy consultant medical need important to us @ djsantibodies.com guitar sailing...